Table 2.
Demographics of the Study Population
| Characteristics | Children failing therapy (n = 97) |
|---|---|
| Mean age in years (SD) | 9.1 ± 4.2 |
| Gender (M/F) | Male = 62 (64%), female = 35 (36%) |
| Mode of HIV transmission | Vertical Transmission |
| Median CD4 cells/μl at the time of failure | 200 (IQR; 34–2094) |
| Median PVL copies/ml at the time of failure | 30,200 (IQR; 2080–444131) |
| Median time to fail therapy (Months) | 32.9 (IQR: 6–96) |
| Treatment history | d4T + 3TC + NVP (43) |
| d4T + 3TC + EFV (7) | |
| AZT +3TC + NVP (31) | |
| AZT +3TC + EFV (3) | |
| IDV +3TC + NVP (1) | |
| ABC +3TC + NVP (4) | |
| TDF +3TC + EFV/NVP (3) | |
| TDF/3TC/RTV + ATV (5) |
3TC, Lamivudine; ABC, Abacavir; ATV, Atazanavir; AZT, Zidovudine; D4T, Stavudine; EFV, Efavirenz; IDV, Indinavir; IQR, interquartile range; NVP, Nevirapine; PVL, plasma viral load; RTV, Ritonavir; TDF, Tenofovir.